ALX Oncology cancer drug claims two FDA fast-track reviewsFresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations Share XALX Oncology cancer drug claims two FDA fast-track reviewshttps://pharmaphorum.com/news/alx-oncology-cancer-drug-claims-two-fda-fast-track-reviews/
Gilead closes in on second CAR-T approval in USThe FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Share XGilead closes in on second CAR-T approval in UShttps://pharmaphorum.com/news/gilead-closes-in-on-second-car-t-approval-in-us/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
Roche files Tecentriq, Avastin combo as a liver cancer therapyRoche has filed for approval of a two-drug combination of its Tecentriq and Avastin drugs in previously-untreated hepatocellular Share XRoche files Tecentriq, Avastin combo as a liver cancer therapyhttps://pharmaphorum.com/news/roche-files-tecentriq-avastin-combo-as-a-liver-cancer-therapy/
China’s Adagene raises $69m for cancer immunotherapiesChinese biotech Adagene has raised $69 million in fourth-round financing to help usher its immuno-oncology drugs – including Share XChina’s Adagene raises $69m for cancer immunotherapieshttps://pharmaphorum.com/news/chinas-adagene-raises-69m-for-cancer-immunotherapies/
Roche steps up Merck challenge with first-line NSCLC approval in USRoche has scored another FDA approval for Tecentriq alongside chemotherapy for previously-untreated, non-squamous non-small cell lung cancer (NSCLC), Share XRoche steps up Merck challenge with first-line NSCLC approval in UShttps://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/
FDA sets January action date for Keytruda in early bladder cancerMerck & Co/MSD has filed for approval of its PD-1 inhibitor Keytruda in a hard-to-treat form of bladder Share XFDA sets January action date for Keytruda in early bladder cancerhttps://pharmaphorum.com/news/fda-sets-january-action-date-for-keytruda-in-early-bladder-cancer/
BMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomaBristol-Myers Squibb’s checkpoint inhibitor combination of Opdivo and low-dose Yervoy is key to its future plans in immuno-oncology, Share XBMS’ Opdivo/Yervoy combo hits a snag in adjuvant melanomahttps://pharmaphorum.com/news/bms-opdivo-yervoy-combo-hits-a-snag-in-adjuvant-melanoma/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
